While the circulating levels of majority of pro-inflammatory adipokine levels, such as tumour necrosis factor alpha (TNF-a), IL-6 and leptin are increased in cancers, some adipokines such as adiponectin are protective against tumourigenesis and its serum levels are usually decreased in the patients with cancer. This evidence concerns the gene ADIPOQ and cancer.